In addition to the studies with AD, the study with Parkinson's disease (PD) pointed to Nrf2 activation (Johnson and Johnson, 2015[120]), while the study with amyotrophic lateral sclerosis (ALS) revealed low Nrf2 protein levels (Sarlette et al., 2008[231]). Here, NFE2L2 is linked to amyotrophic lateral sclerosis.